Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill (2016 - 2025)

Historic Goodwill for Ani Pharmaceuticals (ANIP) over the last 13 years, with Q3 2025 value amounting to $62.5 million.

  • Ani Pharmaceuticals' Goodwill rose 339.92% to $62.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.5 million, marking a year-over-year increase of 339.92%. This contributed to the annual value of $60.0 million for FY2024, which is 11257.22% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Goodwill stood at $62.5 million for Q3 2025, which was up 339.92% from $60.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Goodwill ranged from a high of $62.5 million in Q3 2025 and a low of $3.6 million during Q1 2021
  • Its 5-year average for Goodwill is $32.9 million, with a median of $28.2 million in 2022.
  • Per our database at Business Quant, Ani Pharmaceuticals' Goodwill changed by 0.0% in 2021 and then surged by 68829.61% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Goodwill (Quarter) stood at $27.9 million in 2021, then rose by 1.15% to $28.2 million in 2022, then changed by 0.0% to $28.2 million in 2023, then surged by 112.57% to $60.0 million in 2024, then rose by 4.15% to $62.5 million in 2025.
  • Its last three reported values are $62.5 million in Q3 2025, $60.5 million for Q2 2025, and $60.7 million during Q1 2025.